Patients

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

CRSwNP is a chronic disease of the upper airway, marked by inflammation in the nose and sinuses and the presence of nasal polyps. Nasal polyps are associated with significant morbidity and debilitating symptoms; there is a strong association between severe asthma and CRSwNP with a high comorbidity. Despite available treatments, many people with CRSwNP have uncontrolled symptoms that are impacting their daily life and current treatments are not meeting their needs.

CRSwNP affects up to 4% of the general population, of whom 40% have uncontrolled disease.

Learn more about the positive top-line results from our Phase 2 VIBRANT trial, evaluating verekitug for the treatment of CRSwNP.

Asthma

Asthma is a common chronic lung disease caused by inflammation of the airways. It affects 350 million patients globally and is often underdiagnosed and under-treated. For some people, asthma can interfere with daily life and potentially be life-threatening. Severe asthma is asthma that requires treatment with high-dose inhaled corticosteroids combined with other long-acting medications, or that remains uncontrolled despite proper use of these medications. New treatment options for severe asthma are needed to further improve control of exacerbations and symptoms, and reduce the treatment burden (e.g., need for frequent injections).

Learn more about VALIANT and VALOUR, our ongoing Phase 2 clinical trials evaluating verekitug for the treatment of severe asthma.

Chronic Obstructive Pulmonary Disease (COPD)

COPD is a chronic inflammatory disease of the airways, associated with difficulty breathing and episodic exacerbations that drive morbidity and mortality. It is typically caused by long-term exposure to irritants, most often cigarette smoke. People with a history of asthma are also more likely to have COPD. With COPD, everyday activities may result in shortness of breath and frequent exacerbations, which can result in hospitalization and drive health care utilization. People with COPD are also more likely to acquire lung infections like bronchitis and pneumonia. Current treatments focus primarily on relieving symptoms and reducing exacerbations.

COPD is the fourth leading cause of death worldwide, causing approximately 3.5 million deaths in 2021.

Learn more about VENTURE, our ongoing Phase 2 clinical trial evaluating verekitug for the treatment of COPD.